← Back to Search

Free Radical Scavenger

MBM-01 for Ataxia Telangiectasia

Phase 2
Waitlist Available
Research Sponsored by Matrix Biomed, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have a confirmed diagnosis of A-T.
a) Patients will either have a prior molecular confirmation or will be investigated;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up t25fw will be assessed at baseline, month 3, month 6, and month 9.
Awards & highlights

Study Summary

This trial is testing whether MBM-01 can help people with A-T.

Eligible Conditions
  • Ataxia Telangiectasia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~t25fw will be assessed at baseline, month 3, month 6, and month 9.
This trial's timeline: 3 weeks for screening, Varies for treatment, and t25fw will be assessed at baseline, month 3, month 6, and month 9. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in International Cooperative Ataxia Rating Scale (ICARS)
Secondary outcome measures
Change 8-hydroxy-2- Deoxyguanosine (8-OHdG)
Change in GSH/glutathione Disulfide (GSSG) Concentration Ratio
Change in Nine Hole Peg Test (9HPT) Baseline (Day 1) to end of treatment with MBM-01
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cohort 1Experimental Treatment1 Intervention
Group 1 Patients ≥13 years old will receive a total daily dose of 1200 mg/day. Group 2 - Group 4 Patients 4-12 years old will receive group weight-tiered doses at 17 mg/kg: Group 2 Patients aged 4-12 years weighing 15kg to <25 kg will take 340 mg/day. Group 3 Patients aged 4-12 years weighing 25kg to <35 kg will take 510 mg/day. Group 4 Patients aged 4-12 years weighing ≥35 kg will take 850 mg/day.

Find a Location

Who is running the clinical trial?

Matrix Biomed, Inc.Lead Sponsor
5 Previous Clinical Trials
230 Total Patients Enrolled
The University of Texas Health Science Center, HoustonOTHER
902 Previous Clinical Trials
321,101 Total Patients Enrolled

Frequently Asked Questions

~5 spots leftby Mar 2025